

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

Listing of Claims:

1-10. (Canceled)

11. (Previously Presented) A method of treating Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of: (a) an immunogenic A β fragment effective to produce an immune response comprising antibodies against A β ; and, (b) an adjuvant that augments the immune response to A β , thereby treating Alzheimer's disease.

12-13. (Canceled)

14. (Previously Presented) The method of claim 11, wherein said A β fragment induces an immune response directed against a neoepitope formed by amyloid deposits with respect to amyloid precursor protein (APP).

15-20. (Canceled)

21. (Previously Presented) The method of claim 11, wherein said adjuvant is selected from the group consisting of STIMULON QS-21, 3-De-O-acylated-monophosphoryl lipid A, and alum.

22. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies of at least 1:1000 with respect to A β .

23. (Previously Presented) The method of claim 22, wherein said serum titer of the antibodies is at least 1:5000 with respect to A β .

24. (Previously Presented) The method of claim 11, wherein said immune response is characterized by a serum titer of the antibodies A β corresponding to greater than about four times higher than a serum titer of anti-A β antibodies measured in a pre-treatment control serum sample.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

25. (Previously Presented) The method of claim 24, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

26-58. (Canceled)

59. (Previously Presented) A method of prophylaxis of Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of: (a) an immunogenic A β fragment effective to produce an immune response comprising antibodies against A β and, (b) an adjuvant that augments the immune response to the A β , thereby effecting prophylaxis of Alzheimer's disease.

60. (Previously Presented) The method of claim 59, wherein said A β fragment induces an immune response directed against a neoepitope formed by amyloid deposits with respect to amyloid precursor protein (APP).

61-63. (Canceled)

64. (Previously Presented) The method of claim 59, wherein said adjuvant is selected from the group consisting of STIMULON QS-21, 3 De-O-acylated-monophosphoryl lipid A, and alum.

65. (Previously Presented) The method of claim 59, wherein said immune response is characterized by a serum titer of the anti-A β antibodies of at least 1:1000 with respect to A β .

66. (Previously Presented) The method of claim 65, wherein said serum titer of the antibodies is at least 1:5000 with respect to A β .

67. (Previously Presented) The method of claim 59, wherein said immune response is characterized by a serum titer of the anti-A β antibodies corresponding to greater than about four times higher than a serum titer of anti-A β antibodies measured in a pre-treatment control serum sample.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

68. (Previously Presented) The method of claim 59, wherein said serum titer of the antibodies is measured at a serum dilution of about 1:100.

69. (Canceled)

70. (Previously Presented) The method of claim 11, wherein the subject has a known genetic risk of Alzheimer's disease.

71. (Previously Presented) The method of claim 59, wherein the subject has a known genetic risk of Alzheimer's disease.

72. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-3.

73. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-4.

74. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-5.

75. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-6.

76. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-7.

77. (Canceled)

78. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-10.

79. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 1-12.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

80. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 13-28.

81. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 25-35.

82. (Previously Presented) The method of claim 11, wherein said A β fragment is A β 33-42.

83. (Previously Presented) The method of claim 11, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

84. (Previously Presented) The method of claim 72, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

85. (Previously Presented) The method of claim 73, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

86. (Previously Presented) The method of claim 74, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

87. (Previously Presented) The method of claim 75, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

88. (Previously Presented) The method of claim 76, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

89. (Canceled)

90. (Previously Presented) The method of claim 78, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

91. (Previously Presented) The method of claim 79, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

92. (Previously Presented) The method of claim 80, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

93. (Previously Presented) The method of claim 81, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

94. (Previously Presented) The method of claim 82, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

95. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-3.

96. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-4.

97. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-5.

98. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-6.

99. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-7.

100. (Canceled)

101. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-10.

102. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 1-12.

103. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 13-28.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

104. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 25-35.

105. (Previously Presented) The method of claim 59, wherein said A β fragment is A β 33-42.

106. (Previously Presented) The method of claim 59, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

107. (Previously Presented) The method of claim 95, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

108. (Previously Presented) The method of claim 96, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

109. (Previously Presented) The method of claim 97, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

110. (Previously Presented) The method of claim 98, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

111. (Previously Presented) The method of claim 99, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

112. (Canceled)

113. (Previously Presented) The method of claim 101, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

114. (Previously Presented) The method of claim 102, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

115. (Previously Presented) The method of claim 103, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

Application No.: 09/724,953
Amendment Under 37 CFR §1.312 dated May 27, 2004
Reply to Notice of Allowance March 11, 2004

116. (Previously Presented) The method of claim 104, wherein said A β fragment is linked to a carrier molecule to form a conjugate.

117. (Previously Presented) The method of claim 105, wherein said A β fragment is linked to a carrier molecule to form a conjugate.